Foot Locker Ord Shs (FL)
$28.84 0.85 (3.04%)
19:52 EDT FL Stock Quote Delayed 30 Minutes
Previous Close -
Market Cap 3.37B
PE Ratio 12.88
Volume (Avg. Vol.) 2.92M
Day's Range 28.31 - 29.60
52-Week Range 17.46 - 47.86
Dividend & Yield 1.35 (4.66%)
FL Stock Predictions, Articles, and Foot Locker Ord Shs News
- From InvestorPlace
- From the Web
The consumer spending recovery is underway, and that's great news for these 7 beaten-up apparel stocks to buy on the dip.
Beaten and bruised FL stock is ready to rip higher as the U.S. economy reopens and rebounds in the coming months. Foot Locker has 50% upside.
Foot Locker (FL) earnings for the athletic wear retailer's first quarter of the year have FL stock falling hard on Friday.
Foot Locker (FL) earnings for the athletic wear retailer's fourth quarter of 2019 have FL stock taking off Friday on an EPS beat.
2019 has been one of the best years for stocks in recent memory. Heading into 2020, here are 10 stocks to buy that are struggling to finish well.
Black Friday shoppers did most of their spending online this year. Here are five struggling retail stocks to ditch as a result.
Retail stocks are feeling the heat heading into the critical holiday shopping season. Here are six that are being sold hard.
Xerox is pursuing HP, despite being significantly smaller. Here's what's happening in the stock market today.
Netflix, Amgen, Bristol-Myers Squibb, Aurora Cannabis and Foot Locker are our top stock trades for Tuesday. Here's how to trade them.
Low rates, reduced trade tensions, and strong labor conditions will converge to produce a big rally in these depressed retail stocks.
The stock market has surged to all-time highs in 2019. These oversold stocks haven't. But they are ready to rebound in a big way.
Retail socks have been big laggards so far in 2019, but with trade tensions cooling and rate cuts on the way, they're becoming stocks to buy.
According to Finviz, there are 37 S&P 500 with little debt and lots of profits. Here are the seven such stocks to buy to win in the long run.
From Simply Wall St
This article will reflect on the compensation paid to Anna Protopapas who has served as CEO of Mersana Therapeutics, Inc. (NASDAQ:MRSN) since 2015. This analysis will also look to assess<div><a class="permalink" href="https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-mrsn/mersana-therapeutics/news/what-we-learnt-about-mersana-therapeutics-nasdaqmrsn-ceo-compensation/">Read More...</a></div>
Navellier RatingsPowered by Portfolio Grader